RIGL (Rigel Pharmaceuticals, Inc.) Stock Financials & Earnings

RIGLRigel Pharmaceuticals, Inc.

Mkt Cap$541M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$294M

Net Income (TTM)$367M

EPS (TTM)$19.48

Free Cash Flow (TTM)$76M

Gross Margin93.3%

Op. Margin42.6%

Net Margin124.7%

FCF Margin25.7%

P/S Ratio (TTM)1.8x

P/E Ratio (TTM)1.5x

YoY Rev Growth+64.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$26M	$25M	-$13M
Q2 23	$27M	$26M	-$5M
Q3 23	$28M	$27M	-$4M
Q4 23	$36M	$32M	$2M
Q1 24	$30M	$28M	-$7M
Q2 24	$37M	$34M	$447K
Q3 24	$55M	$47M	$14M
Q4 24	$58M	$52M	$17M
Q1 25	$53M	$49M	$13M
Q2 25	$102M	$97M	$61M
Q3 25	$69M	$65M	$28M
Q4 25	$70M	$64M	$23M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$10M	—	—	$28M
Q2 23	$5M	$26M	—	—
Q3 23	$6M	—	—	$25M
Q4 23	$3M	$26M	$544K	—
Q1 24	$6M	—	—	$28M
Q2 24	$6M	—	—	$28M
Q3 24	$6M	—	—	$27M
Q4 24	$6M	—	—	$30M
Q1 25	$8M	—	—	$28M
Q2 25	$7M	—	—	$29M
Q3 25	$7M	—	—	$29M
Q4 25	$11M	—	—	$30M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$40M	$18M	$59M
Q2 23	$49M	$16M	$64M
Q3 23	$45M	$17M	$62M
Q4 23	$33M	$24M	$57M
Q1 24	$26M	$24M	$50M
Q2 24	$36M	$13M	$49M
Q3 24	$52M	$9M	$61M
Q4 24	$57M	$21M	$77M
Q1 25	$46M	$31M	$77M
Q2 25	$53M	$55M	$108M
Q3 25	$49M	$89M	$137M
Q4 25	$41M	$114M	$155M

Shares Outstanding

Revenue Per Employee

Revenue / Employee